SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (499)7/21/1999 10:44:00 AM
From: scaram(o)uche  Read Replies (1) | Respond to of 3158
 
Geeeeeze, great call(s). David S. and [widely rumored, I have no direct evidence] the Prudent Bear Fund were also on the wrong side of AGPH. However, in that instance, they had plenty of time to cover.

The poor performance of Jim Cramer (TSC has taken shots at several companies that have been targeted for bear runs) and Tice et al. (Prudent Bear) has been well-documented.

Those who take shots at biotech when research has been so severely discounted are learning a few lessons.



To: Biomaven who wrote (499)7/26/1999 12:37:00 PM
From: W PAUL  Read Replies (2) | Respond to of 3158
 
UK's Shire (Adderall & galantamine) - SHPGY - has announced merging/
buying Roberts Pharm -RPC. I know nothing about the latter. The resulting
market cap will be about $2.3b.
Initial reaction in London was positive but now Shire is off 10% and RPC up though
you would not have guessed from the angry reaction of many RPC shareholders
on Yahoo etc
I would be grateful for your reaction if you have one.



HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News